Program
heat-labile enterotoxin, E coli
Also written as “AD17002” and “AD17002 + Formulation buffer”.
Its studies are mostly in COVID-19 · Rhinitis, Allergic, led by Advagene Biopharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Advagene Biopharma | 51 open or running | phase 3since Aug 5, 2022 | Aug 8, 2019 | none ahead |
Also a collaborator on its studies: Clinipace Worldwide.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2019First study: phase 2 study in Rhinitis, AllergicFirst studyNCT04088721 · 48 enrolled · Taiwan
- Oct 4, 2021Phase 2 study in COVID-19NCT05069610 · 30 enrolled · Taiwan
- Aug 5, 2022Phase 3 study in COVID-19NCT05541510 · 180 enrolled · Indonesia
- Jul 26, 2023Phase 2 study in Pulmonary EosinophiliaNCT05985694 · 40 enrolled · Taiwan
- Sep 4, 2025Phase 2 study in Pulmonary EosinophiliaNCT07250594 · 126 planned · Taiwan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07250594Pulmonary Eosinophilia · Taiwan | 2 | Not yet recruiting | Oct 2026 | 126 |
| NCT05985694Pulmonary Eosinophilia · Taiwan | 2 | Completed | Jan 28, 2025 | 40 |
| NCT05541510COVID-19 · Indonesia | 3 | Terminated | Aug 5, 2024 | 180 |
| NCT05069610COVID-19 · Taiwan | 2 | Completed | Oct 31, 2023 | 30 |
| NCT04088721Rhinitis, Allergic · Taiwan | 2 | Completed | Jul 30, 2020 | 48 |
How it is read
Names in the registry
- “AD17002”, 4 entries
- “AD17002 + Formulation buffer”, 1 entry
Codes read as this program: AD17002.
Conditions, from the studies’ own filings
- COVID-19, 2 studies
- Rhinitis, Allergic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.